ProCE Banner Activity

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Podcast Episodes

Caitlin Costello, MD, discusses the role and safety of bispecific antibodies approved for the treatment of relapsed/refractory multiple myeloma as well as emerging data and clinical trials with this treatment approach.

Released: October 24, 2024

Expiration: October 23, 2025

Share

Faculty

Caitlin Costello

Caitlin Costello, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Provided by

Provided by the National Comprehensive Cancer Network in collaboration with Clinical Care Options, LLC.

ProCE Banner
ProCE Banner

Supporters

Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Supported by a grant from Pfizer Inc. Supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Pfizer, Inc.

Regeneron Pharmaceuticals, Inc

Disclosure

Primary Author

Caitlin Costello, MD

Clinical Professor of Medicine
Director, Multiple Myeloma Program
Division of Blood and Marrow Transplantation
Moores Cancer Center
UC San Diego
La Jolla, California

Caitlin Costello, MD: consultant/advisor/speaker: Bristol Myers Squibb, Genentech, Janssen, Karyopharm, Pfizer, Regeneron.